Takemasa Tsuji, PhD Takemasa Tsuji, PhD

Takemasa Tsuji


Special Interests:

Utilizing tumor antigen-specific CD4+ T cells to maximize the therapeutic effect of cancer immunotherapy Development of therapeutic gene products (T cell receptors and chimeric antigen receptors) for adoptive T cell therapy Identification of immunotherapy targets Characterizing spontaneous and vaccine-induced immune responses against tumor antigens

About Takemasa Tsuji


Dr. Takemasa Tsuji joined the faculty in 2013 as an Assistant Professor of Oncology in the Center for Immunotherapy at Roswell Park Comprehensive Cancer Center. After obtaining his PhD, he conducted laboratory experiments as a postdoctoral research fellow in the laboratories of Dr. Takashi Nishimura (Hokkaido University, JAPAN), Dr. Lloyd J. Old (Ludwig Institute for Cancer Institute/Memorial Sloan-Kettering Cancer Center, NY), and Dr. Kunle Odunsi (Roswell Park Comprehensive Cancer Center, NY). His research during postdoctoral training has been focused on understanding the mechanisms of immunologic recognition of human cancers such that specific immunotherapies can be applied on a personalized basis.


Roswell Park Comprehensive Cancer Center
  • Assistant Professor of Oncology
  • Assistant Member, Center for Immunotherapy
  • Assistant Member, Department of Immunology


Education and Training:

  • 1999 - PhD (Science) - Graduate School of Science, Hokkaido University, Sapporo, Hokkaido
  • 1996 - MS - Graduate School of Science, Hirosaki University, Hirosaki, Aomori


  • 2013 - Postdoctoral Fellowship - Roswell Park Comprehensive Cancer Center, Buffalo, NY
  • 2012 - Postdoctoral Fellowship - Memorial Sloan-Kettering Cancer Center, New York, NY
  • 2005 - Postdoctoral Fellowship, Immunology - Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido
  • 2000 - Research Fellowship - Graduate School of Science, Hokkaido University, Sapporo, Hokkaido

Professional Memberships:

  • American Association of Cancer Research


Research Overview:

Dr. Tsuji’s research in the past few years has led to the identification and characterization of a unique CD4+ T cell subset, which is named “tumor-recognizing CD4+ helper T cell (TR-CD4 cell)," that directly recognizes cancer cells. Through direct recognition of cancer cells, TR-CD4 cells significantly inhibit tumor cell growth and potently enhance anti-tumor functions of cytotoxic CD8+ T cells. He also elucidated novel antigen presentation mechanisms that are involved in the presentation of intracellular tumor antigen proteins to CD4+ T cells. He recently established a method to generate large numbers of TR-CD4 cells by gene-engineering with T cell receptor (TCR) gene for the development of novel tumor adoptive T cell therapy using TR-CD4 cells.


Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment